Beilu Pharmaceutical

Main products are Contrast media, psychoneurosis traditional Chinese medicine and endocrinology drugs

[Beilu Pharmaceutical @beilupharma]

📷 Exciting news! Beilu Pharma's Gadobutrol API has received the CEP certificate, marking a key milestone for its sale in the EU. This boosts its global standing and supports contrast-enhanced MRI applications.

https://t.co/qQnvdY1arf

#PharmaNews #HealthcareInnovation #MRI

[Beilu Pharmaceutical @beilupharma]

What Comes to Mind When You Hear "Beilu"? | Dozie & Dozie's Team

[Beilu Pharmaceutical @beilupharma]

Exciting news! Beilu Pharma's Dyclonine Hydrochloride API is now approved by NMPA, marking a key milestone in local anesthetic solutions. Get ready for enhanced pain relief and product innovation!

#PharmaceuticalInnovation #Healthcare #BeiluPharma

https://t.co/qA5t0M6qAy

[Beilu Pharmaceutical @beilupharma]

Exciting news! Beilu Pharma's Ioversol Injection has received approval from the NMPA. This enhances our iodine contrast agent portfolio and strengthens market competitiveness. Stay tuned for its launch!

#BeiluPharma #IoversolInjection #MedicalInnovation

https://t.co/MqZIgIxInD

[Beilu Pharmaceutical @beilupharma]

Beilu Pharma's Gadobutrol API receives approval from NMPA, marking a milestone for the company’s "API + Formulation" business model. This approval enhances its market competitiveness and product pipeline in contrast media.

https://t.co/td6WkMLsRo

#BeiluPharma

[Beilu Pharmaceutical @beilupharma]

Exciting news from Beilu Pharma! We've just received the Drug Registration Certificate for Mupirocin Ointment, approved by the NMPA. This topical antibiotic is essential for treating skin infections. We're gearing up for its market launch soon!

https://t.co/GMUZoj9u1o

[Beilu Pharmaceutical @beilupharma]

Join Beilu Pharma at CPHI China 2026! Discover contrast media, anti-diabetic, and TCM innovations. Meet us at Stand E1E25, Shanghai, June 16-18. Don't miss out!

#PharmaInnovation #CPHIChina

https://t.co/djF9ML1NKz

[Beilu Pharmaceutical @beilupharma]

Exciting news! Beilu Pharma's Iopromide Injection just got the green light from NMPA. As part of the NRDL, this approval enhances their iodinated contrast media lineup. Stay tuned for more innovations!

#PharmaInnovation #HealthcareAdvancements

🔗https://t.co/1qaDk4NJgc

[Beilu Pharmaceutical @beilupharma]

🌐 [News] Beilu Pharmaceutical's HK subsidiary secures registration for Jiuwei Sleep-Aid Granules, opening doors to the Hong Kong market and beyond. A major leap for TCM globalization!

Read more: https://t.co/iEJzT3epYi

#TraditionalChineseMedicine #PharmaNews #GlobalExpansion

[Beilu Pharmaceutical @beilupharma]

🚀 New Product Approval: Beilu Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets just received NMPA approval! Fast-acting, convenient, and discreet—designed for patient ease and privacy.

Learn more 👉 https://t.co/RhMaglXgDZ

#PharmaNews #Innovation

[Beilu Pharmaceutical @beilupharma]

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets (15 mg/500 mg).

https://t.co/IJPE8xDlQ9

[Beilu Pharmaceutical @beilupharma]

Exciting news! 🎉 Beilu Pharma has secured NMPA approval for their new product, Iomeprol Injection, a non-ionic monomeric X-ray contrast agent developed by Bracco Group. This approval adds to Beilu Pharma's iodine contrast agent portfolio. 🚀🥼
https://t.co/xe8iLB7WyS

[Beilu Pharmaceutical @beilupharma]

https://t.co/K7DTilvzeo Gadobutrol Injection Proposed for Selection in the 11th National Drug Centralized Procurement

[Beilu Pharmaceutical @beilupharma]

🚀 Big News! Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has achieved GMP certification from Brazil's ANVISA! This milestone sets the stage for expanding into Brazil and beyond. 🌎📈

https://t.co/5uuJKD6dBK

#BeiluPharma #HichiPharma #Brazil #PharmaNews

[Beilu Pharmaceutical @beilupharma]

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical, Receives Approval for Iomeprol API

https://t.co/umVLRe8qaF

[Beilu Pharmaceutical @beilupharma]

Beilu Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Indian Registration Certificate
https://t.co/PdjH52CYqo

[Beilu Pharmaceutical @beilupharma]

Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch

https://t.co/JOBD7BqbfI

[Beilu Pharmaceutical @beilupharma]

Gadobenate Dimeglumine Injection and Gadopentetate Dimeglumine Injections Proposed for Selection in Xinjiang Uygur Autonomous Region's 26-Province Alliance Centralized Volume-Based Procurement
https://t.co/jBh4DOlvGD

[Beilu Pharmaceutical @beilupharma]

Beilu Pharmaceutical Wins Emerging Pharmaceutical Internationalization Award at CPHI China

https://t.co/rIYgZYxMGy

[Beilu Pharmaceutical @beilupharma]

Beilu Pharmaceutical's Iohexol Injection Receives Marketing Authorization in Hungary

https://t.co/OLnicNAIPn